Hepion Pharmaceuticals Inc (HEPA)

[mick]

very good read my friend/ 'ContraVir Pharmaceutcals (CTRV)'

re;
End of year 2016 should be very very interesting in a positive way

Based on today's PR ( excerpts)

..the company (CTRV) has begun enrolling the next dosing group in its head-to-head Phase 2a dose-escalation study comparing the safety and efficacy of ContraVir's CMX157 to tenofovir disoproxil fumarate (TDF, marketed by Gilead Sciences as Viread®) in patients with chronic hepatitis B (HBV). ContraVir expects to complete the remaining two escalation cohorts and report top-line results by year-end 2016.

the DSMB approved proceeding to a higher dose in the ongoing Phase 2a dose escalation trial per study protocol.

James Sapirstein, CEO of ContraVir - "We look forward to reporting final Phase 2a data by year end, and continue to believe that CMX157 has the ideal attributes needed for use as a component of a future combination drug strategy where drug-drug interactions put high demands on safety."

Notably, a 25 mg dose of CMX157 achieved comparable HBV viral load reduction to the standard 300 mg dose of Viread®, but with significantly reduced systemic levels of active tenofovir. Results from the completed Phase 1b and ongoing Phase 2a clinical trials suggest that CMX157 is a highly potent HBV antiviral that may mitigate the risk of kidney and bone toxicities that are associated with Viread